Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett Sells 14,380 Shares

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Immunome Price Performance

Shares of IMNM stock opened at $14.99 on Friday. Immunome, Inc. has a 1 year low of $6.65 and a 1 year high of $30.96. The firm has a fifty day moving average price of $14.51 and a 200-day moving average price of $16.24. The company has a market cap of $898.94 million, a price-to-earnings ratio of -1.99 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Equities research analysts expect that Immunome, Inc. will post -1.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on IMNM. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Tuesday, August 13th. Piper Sandler cut their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $29.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IMNM. Quest Partners LLC bought a new position in Immunome in the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Immunome in the 2nd quarter worth $97,000. Arizona State Retirement System boosted its holdings in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after buying an additional 918 shares during the period. EntryPoint Capital LLC boosted its holdings in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after buying an additional 5,466 shares during the period. Finally, Jump Financial LLC bought a new position in Immunome in the 4th quarter worth $172,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.